Effects of Etanercept in Patients with the Metabolic Syndrome

Overview

Journal Arch Intern Med

Specialty General Medicine

Date 2006 Apr 26

PMID 16636217

Citations 108

Authors

L Elizabeth Bernstein

Jacqueline Berry

Sunnie Kim

Bridget Canavan

Steven K Grinspoon

Affiliations

Soon will be listed here.

Abstract

Background: Adipose-derived cytokines, including tumor necrosis factor alpha, may contribute to the inflammation that occurs in the metabolic syndrome. We investigated the effects of inhibition of tumor necrosis factor alpha with etanercept in patients with the metabolic syndrome.

Methods: Fifty-six subjects with the metabolic syndrome were randomized to administration of either etanercept or identical placebo, 50 mg subcutaneously once a week for 4 weeks. The C-reactive protein level was the primary end point. Effects on other inflammatory markers (including fibrinogen, interleukin 6, and adiponectin), insulin sensitivity, lipid levels, and body composition were also determined.

Results: Baseline characteristics were similar between the groups. Two subjects dropped out of each group, and etanercept was well tolerated throughout the study. The C-reactive protein levels decreased significantly in the treated compared with the placebo group (-2.4 +/- 0.4 vs 0.5 +/- 0.7 mg/L; P<.001). Adiponectin levels rose significantly in the etanercept group compared with the placebo group (0.8 +/- 0.4 vs -0.3 +/- 0.3 microg/mL; P = .03). Fibrinogen levels decreased (-68 +/- 16 vs -2 +/- 31 mg/dL [-2.0 +/- 0.47 vs -0.06 +/- 0.91 micromol/L]; P = .04) and interleukin 6 levels tended to decrease (-1.2 +/- 0.8 vs 0.5 +/- 0.5 ng/L; P = .07) in the etanercept-treated subjects compared with placebo, respectively. No changes occurred in body composition parameters or insulin sensitivity, but high-density lipoprotein levels tended to decrease in the etanercept group (-1 +/- 1 vs 2 +/- 1 mg/dL [-0.03 +/- 0.03 vs 0.05 +/- 0.03 mmol/L]; P = .06) compared with the placebo group.

Conclusions: Etanercept reduces C-reactive protein levels and tends to improve other inflammatory cardiovascular risk indexes in patients with the metabolic syndrome. Etanercept may interrupt the inflammatory cascade that occurs with abdominal obesity. Further, longer-term studies are needed to determine the effects of tumor necrosis factor alpha inhibition on cardiovascular disease in patients with the metabolic syndrome.

Citing Articles

Exploring the Interplay between Fatty Acids, Inflammation, and Type 2 Diabetes.

Nicholas D, Mbongue J, Garcia-Perez D, Sorensen D, Ferguson Bennit H, De Leon M Immuno. 2024; 4(1):91-107.

PMID: 39606781 PMC: 11600342. DOI: 10.3390/immuno4010006.

Interleukin-receptor antagonist and tumour necrosis factor inhibitors for the primary and secondary prevention of atherosclerotic cardiovascular diseases.

Marti-Carvajal A, Gemmato-Valecillos M, Monge Martin D, Dayer M, Alegria-Barrero E, De Sanctis J Cochrane Database Syst Rev. 2024; 9:CD014741.

PMID: 39297531 PMC: 11411914. DOI: 10.1002/14651858.CD014741.pub2.

Is it time to rethink the relationship between adipose inflammation and insulin resistance?.

Rosen E, Kajimura S J Clin Invest. 2024; 134(17).

PMID: 39225103 PMC: 11364379. DOI: 10.1172/JCI184663.

MASH as an emerging cause of hepatocellular carcinoma: current knowledge and future perspectives.

Karin M, Kim J Mol Oncol. 2024; 19(2):275-294.

PMID: 38874196 PMC: 11793012. DOI: 10.1002/1878-0261.13685.

Fasting and Glucose Metabolism Differentially Impact Peripheral Inflammation in Human Type 2 Diabetes.

Kalantar G, Saraswat S, SantaCruz-Calvo S, Gholamrezaeinejad F, Javidan A, Agrawal M Nutrients. 2024; 16(10.

PMID: 38794641 PMC: 11124302. DOI: 10.3390/nu16101404.

References

Arita Y, Kihara S, Ouchi N, Maeda K, Kuriyama H, Okamoto Y . Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation. 2002; 105(24):2893-8. DOI: 10.1161/01.cir.0000018622.84402.ff. View

Borkan G, Gerzof S, Robbins A, Hults D, Silbert C, Silbert J . Assessment of abdominal fat content by computed tomography. Am J Clin Nutr. 1982; 36(1):172-7. DOI: 10.1093/ajcn/36.1.172. View

You T, Yang R, Lyles M, Gong D, Nicklas B . Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab. 2004; 288(4):E741-7. DOI: 10.1152/ajpendo.00419.2004. View

Wang B, Jenkins J, Trayhurn P . Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab. 2004; 288(4):E731-40. DOI: 10.1152/ajpendo.00475.2004. View

Malik S, Wong N, Franklin S, Pio J, Fairchild C, Chen R . Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care. 2005; 28(3):690-3. DOI: 10.2337/diacare.28.3.690. View

Ridker P, Rifai N, Pfeffer M, Sacks F, Lepage S, Braunwald E . Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000; 101(18):2149-53. DOI: 10.1161/01.cir.101.18.2149. View

Kern P, Saghizadeh M, Ong J, Bosch R, Deem R, Simsolo R . The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest. 1995; 95(5):2111-9. PMC: 295809. DOI: 10.1172/JCI117899. View

Ofei F, Hurel S, Newkirk J, Sopwith M, Taylor R . Effects of an engineered human anti-TNF-alpha antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes. 1996; 45(7):881-5. DOI: 10.2337/diab.45.7.881. View

Hotamisligil G, Shargill N, Spiegelman B . Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091):87-91. DOI: 10.1126/science.7678183. View

10.

Saad M, Anderson R, Laws A, Watanabe R, Kades W, Chen Y . A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study. Diabetes. 1994; 43(9):1114-21. DOI: 10.2337/diab.43.9.1114. View

11.

Schmeling H, Mathony K, John V, Keysser G, Burdach S, Horneff G . A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study. Ann Rheum Dis. 2001; 60(4):410-2. PMC: 1753601. DOI: 10.1136/ard.60.4.410. View

12.

Xydakis A, Case C, Jones P, Hoogeveen R, Liu M, OBrian Smith E . Adiponectin, inflammation, and the expression of the metabolic syndrome in obese individuals: the impact of rapid weight loss through caloric restriction. J Clin Endocrinol Metab. 2004; 89(6):2697-703. DOI: 10.1210/jc.2003-031826. View

13.

Alberti K, Zimmet P . Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998; 15(7):539-53. DOI: 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S. View

14.

Tsimberidou A, Waddelow T, Kantarjian H, Albitar M, Giles F . Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003; 27(5):375-80. DOI: 10.1016/s0145-2126(02)00082-6. View

15.

Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y . Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001; 103(8):1057-63. DOI: 10.1161/01.cir.103.8.1057. View

16.

Ford E, Giles W, Mokdad A . Increasing prevalence of the metabolic syndrome among u.s. Adults. Diabetes Care. 2004; 27(10):2444-9. DOI: 10.2337/diacare.27.10.2444. View

17.

Drynda S, Kuhne C, Kekow J . Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. Ann Rheum Dis. 2002; 61(3):254-6. PMC: 1754023. DOI: 10.1136/ard.61.3.254. View

18.

Stephens J, Butts M, Pekala P . Regulation of transcription factor mRNA accumulation during 3T3-L1 preadipocyte differentiation by tumour necrosis factor-alpha. J Mol Endocrinol. 1992; 9(1):61-72. DOI: 10.1677/jme.0.0090061. View

19.

Pischon T, Girman C, Hotamisligil G, Rifai N, Hu F, Rimm E . Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004; 291(14):1730-7. DOI: 10.1001/jama.291.14.1730. View

20.

Abbasi F, Brown Jr B, Lamendola C, McLaughlin T, Reaven G . Relationship between obesity, insulin resistance, and coronary heart disease risk. J Am Coll Cardiol. 2002; 40(5):937-43. DOI: 10.1016/s0735-1097(02)02051-x. View